![]() Seizures and seizure-like activity have been reported in patients receiving scopolamine. Also, monitor patients for new or worsening psychiatric symptoms during concomitant treatment with other drugs that are associated with similar psychiatric effects. Monitor patients for new or worsening psychiatric symptoms during treatment with scopolamine transdermal system. Other psychiatric reactions have also been reported, including acute toxic psychosis, agitation, speech disorder, hallucinations, paranoia, and delusions. Scopolamine has been reported to exacerbate psychosis. Advise patients to immediately remove the transdermal system and contact their healthcare provider if they experience symptoms of acute angle closure glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Monitor intraocular pressure in patients with open angle glaucoma and adjust glaucoma therapy during scopolamine transdermal system use, as needed. The mydriatic effect of scopolamine may cause an increase in intraocular pressure resulting in acute angle closure glaucoma. ![]() Warnings and Precautions Acute Angle Closure Glaucoma Reactions have included rash generalized and erythema. ![]() hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system.Scopolamine transdermal system is contraindicated in patients with: Transdermal system: a circular, flat, tan-colored transdermal system imprinted with “Scopolamine 1 mg/3 days” Contraindications ![]() Remove the transdermal system 24 hours following surgery. If therapy is required for longer than 3 days, remove the first transdermal system and apply a new scopolamine transdermal system behind the other ear.įor surgeries other than cesarean section: Apply one scopolamine transdermal system the evening before scheduled surgery. Upon removal, fold the used transdermal system in half with the sticky side together, and discard in household trash in a manner that prevents accidental contact or ingestion by children, pets or others.Īpply one scopolamine transdermal system to the hairless area behind one ear at least 4 hours before the antiemetic effect is required – for use up to 3 days.If the transdermal system becomes displaced, discard the transdermal system, and apply a new transdermal system on the hairless area behind the other ear.After the transdermal system is applied on the dry skin behind the ear, wash hands thoroughly with soap and water and dry hands.Apply the transdermal system to the skin in the postauricular area (hairless area behind one ear).Only wear one transdermal system at any time.Each scopolamine transdermal system is formulated to deliver in vivo approximately 1 mg of scopolamine over 3 days.Scopolamine Patch Dosage and Administration Important Application and Removal Instructions ![]()
0 Comments
Leave a Reply. |